Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fres...

CEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will supp...

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...

A rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...

Heads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Indian stock markets experienced sharp cuts on Thursday, with Nifty and Sensex declining due to rising oil prices and a falling rupee. Sell...

London’s FTSE 100 edged lower as losses in energy majors and AstraZeneca weighed on the index amid thin holiday trading. Weak crude prices ...

Prime Minister Keir Starmer announced AstraZeneca will invest 300 million pounds in UK life sciences. This significant investment secures 1...

European shares dipped on Wednesday, as investors turned their focus to a packed day of corporate earnings, while a continuing U.S.-Iran im...

The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...

AstraZeneca has confirmed that several of its employees in China are under investigation for potential illegal data collection and unapprov...

On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $1...

"Sun Pharma has now acquired the rights to trademarks Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of Ast...

Britain's AstraZeneca on Monday rejected a sweetened 55-pounds-a-share offer from Pfizer.

AstraZeneca Pharma today said its board has approved delisting of the company's shares from bourses, including BSE and the National Stock E...

Shares of AstraZeneca Pharma rose by 3 per cent as its board has approved delisting of the company's shares from bourses like NSE, BSE etc.